Terms: = Prostate cancer AND FANCA, MGC75158, 2175, ENSG00000187741, FA-H, FA, FAA, FANCH, FA1, FACA
173 results:
1. Urinary fatty acid biomarkers for prostate cancer detection.
Noriega Landa E; Quaye GE; Su X; Badmos S; Holbrook KL; Polascik TJ; Adams ES; Deivasigamani S; Gao Q; Annabi MH; Habib A; Lee WY
PLoS One; 2024; 19(2):e0297615. PubMed ID: 38335180
[TBL] [Abstract] [Full Text] [Related]
2. Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
Cancel M; Crottes D; Bellanger D; Bruyère F; Mousset C; Pinault M; Mahéo K; Fromont G
Prostate; 2024 Mar; 84(4):358-367. PubMed ID: 38112233
[TBL] [Abstract] [Full Text] [Related]
3. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
4. Genetic predisposition to metabolically unfavourable adiposity and prostate cancer risk: A Mendelian randomization analysis.
Perez-Cornago A; Smith-Byrne K; Hazelwood E; Watling CZ; Martin S; Frayling T; Lewis S; Martin RM; Yaghootkar H; Travis RC; Key TJ
Cancer Med; 2023 Aug; 12(15):16482-16489. PubMed ID: 37305903
[TBL] [Abstract] [Full Text] [Related]
5. Physicochemical and Biopharmaceutical Controllability of New Self-Assembled Fatty Acid Conjugated Leuprolide for the Enhanced Anticancer Activity.
Ngo HV; Bak HE; Nguyen HD; Lee KW; Park C; Lee BJ
Int J Nanomedicine; 2023; 18():2325-2344. PubMed ID: 37168738
[TBL] [Abstract] [Full Text] [Related]
6. In vitro and in vivo Evaluation of Folic Acid Modified DOX-Loaded
Deng H; Wang Y; Zhou Y; Zhai D; Chen J; Hao S; Chen X
Int J Nanomedicine; 2023; 18():2003-2015. PubMed ID: 37077940
[TBL] [Abstract] [Full Text] [Related]
7. Evaluating Germline Testing Panels in Southern African Males With Advanced prostate cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract] [Full Text] [Related]
8. Targeted PEGylated Chitosan Nano-complex for Delivery of Sodium Butyrate to prostate cancer: An In Vitro Study.
Zamanvaziri A; Meshkat M; Alazmani S; Khaleghi S; Hashemi M
Technol Cancer Res Treat; 2023; 22():15330338231159223. PubMed ID: 36855824
[No Abstract] [Full Text] [Related]
9. Gold Nanoparticles Conjugated with Dendrigraft Poly-L-lysine and Folate-Targeted Poly(ethylene glycol) for siRNA Delivery to prostate cancer.
Minassian G; Ghanem E; Hage RE; Rahme K
Nanotheranostics; 2023; 7(2):152-166. PubMed ID: 36793347
[TBL] [Abstract] [Full Text] [Related]
10. VMAT partial arc technique decreases dose to organs at risk in whole pelvic radiotherapy for prostate cancer when compared to full arc VMAT and IMRT.
Bartlett GK; Njeh CF; Huang KC; DesRosiers C; Guo G
Med Dosim; 2023 Spring; 48(1):8-15. PubMed ID: 36319515
[TBL] [Abstract] [Full Text] [Related]
11. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with fanca mutation: A case report.
Lai YH; Tung KC; Chen SC
Medicine (Baltimore); 2022 Sep; 101(39):e30719. PubMed ID: 36181052
[TBL] [Abstract] [Full Text] [Related]
12. The adipocyte microenvironment and cancer.
Mukherjee A; Bilecz AJ; Lengyel E
Cancer Metastasis Rev; 2022 Sep; 41(3):575-587. PubMed ID: 35941408
[TBL] [Abstract] [Full Text] [Related]
13. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic prostate cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract] [Full Text] [Related]
14. Progress in the drug encapsulation of poly(lactic-
Dodda JM; Remiš T; Rotimi S; Yeh YC
J Mater Chem B; 2022 Jun; 10(22):4127-4141. PubMed ID: 35593381
[TBL] [Abstract] [Full Text] [Related]
15. Foliate-Targeting Quantum Dots-
Pilch J; Kowalik P; Kowalczyk A; Bujak P; Kasprzak A; Paluszkiewicz E; Augustin E; Nowicka AM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163186
[TBL] [Abstract] [Full Text] [Related]
16. Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation-dependence on GPR120.
Liang P; Henning SM; Grogan T; Elashoff D; Ye H; Cohen P; Aronson WJ
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):539-546. PubMed ID: 35075215
[TBL] [Abstract] [Full Text] [Related]
17. Effect of Hydroxyl Groups Esterification with Fatty Acids on the Cytotoxicity and Antioxidant Activity of Flavones.
Kubiak-Tomaszewska G; Roszkowski P; Grosicka-Maciąg E; Strzyga-Łach P; Struga M
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056733
[TBL] [Abstract] [Full Text] [Related]
18. Causal roles of circulating adiponectin in osteoporosis and cancers.
He B; Zhao J; Zhang M; Yin L; Quan Z; Ou Y; Huang W
Bone; 2022 Feb; 155():116266. PubMed ID: 34844025
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract] [Full Text] [Related]
20. Identification of prostate cancer using multiparametric MR imaging characteristics of prostate tissues referenced to whole mount histopathology.
Gibbons M; Starobinets O; Simko JP; Kurhanewicz J; Carroll PR; Noworolski SM
Magn Reson Imaging; 2022 Jan; 85():251-261. PubMed ID: 34666162
[TBL] [Abstract] [Full Text] [Related]
[Next]
